Loss of YTHDF2 enhances Th9 programming and CAR-Th9 cell antitumor efficacy
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA1175660 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR31061210_1.fastq.gz | Fastqsanger.gz | |||
| SRR31061210_2.fastq.gz | Fastqsanger.gz | |||
| SRR31061211_1.fastq.gz | Fastqsanger.gz | |||
| SRR31061211_2.fastq.gz | Fastqsanger.gz | |||
| SRR31061212_1.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 50 |
Similar Datasets
Project description:CD4+ T cells differentiate into various subsets, including T helper 1 (Th1), Th2, Th9, Th17, and regulatory T cells, which are essential in immune responses and cancer immunotherapy. However, the role of RNA N6-methyladenosine (m6A) modification in this differentiation remains unclear. Here, we demonstrate that YTHDF2, a key m6A reader protein known to destabilize m6A-modified mRNA, negatively regulates Th9 cell differentiation. Ablation of Ythdf2 in both mouse and human naïve CD4+ T cells significantly promotes Th9 differentiation by stabilizing Gata3 and Smad3 mRNA under IL-4 and TGF-β signaling. Ythdf2-deficient Th9 cells produce higher levels of IL-9 and IL-21, leading to increased tumor infiltration and cytotoxicity by CD8+ T and NK cells, thereby improving antitumor activity versus wild-type Th9 cells. Moreover, YTHDF2 depletion in CAR-Th9 cells enhances immune activation, reduces terminal differentiation, and augments antitumor efficacy. Targeting YTHDF2 thus represents a promising strategy for enhancing Th9 and CAR-Th9 cell-based cancer immunotherapies.
2025-06-17 | GSE279983 | GEO
Project description:CXCL13 expression is highly elevated in T cells from patients who respond to PD-1 blockade, suggesting that CXCL13 may play a role in boosting T cell antitumor responses. Compared to conventional Th1/Tc1 cells, Th9/Tc9 cells exhibit stronger antitumor functions, and IL-9 plays a critical role in mediating their antitumor efficacy. Therefore, we investigate the respective effects of CXCL13 and IL-9 on CAR T cells.
2025-09-11 | GSE283222 | GEO
Project description:Chimeric antigen receptor–T (CAR-T) cell therapies can eliminate relapsed and refractory tumors, but the durability of antitumor activity requires in vivo persistence. Differential signaling through the CAR costimulatory domain can alter the T cell metabolism, memory differentiation, and influence long-term persistence. CAR-T cells costimulated with 4-1BB or ICOS persist in xenograft models but those constructed with CD28 exhibit rapid clearance. Here, we show that a single amino acid residue in CD28 drove T cell exhaustion and hindered the persistence of CD28-based CAR-T cells and changing this asparagine to phenylalanine (CD28-YMFM) promoted durable antitumor control. In addition, CD28-YMFM CAR-T cells exhibited reduced T cell differentiation and exhaustion as well as increased skewing toward Th17 cells. Reciprocal modification of ICOS-containing CAR-T cells abolished in vivo persistence and antitumor activity. This finding suggests modifications to the costimulatory domains of CAR-T cells can enable longer persistence and thereby improve antitumor response.
2020-02-11 | GSE145007 | GEO
Project description:Radiation induced YTHDF2 in dendritic cells impairs antitumor immunity
| PRJNA1334374 | ENA
Project description:Self-renewing stem-like T cells promote the efficacy of cancer immunotherapy and are a heterogeneous population with sub-lineages demonstrating different degrees of stemness. At the apex of this hierarchy is long-term (LT) stem-like T cells with the highest capacity of persistence, repopulation and response to immune checkpoint inhibitors (ICI). However, the pathway that establishes the hierarchy of stemness in chimeric antigen receptor (CAR) T cells and its role in antitumor efficacy of CAR T cells are unclear. Here, we demonstrate that LT stem-like differentiation and antitumor immunity of CAR T cells are dose-dependently regulated by BACH2. Pre-infusion LT stem-like CAR T cells showed epigenetic activation of BACH2 and superior antitumor response in mice and humans. After clearing tumor in vivo, LT stem-like T cells emerged as a CAR subset that transcriptionally and epigenetically upregulated BACH2 and downregulated TOX. Loss-of-function experiments revealed an essential role of BACH2 in the antitumor response of CAR T cells and the transcriptional program of LT stem-like CAR T cells. In exhaustion-prone GD2 CAR T cells with high tonic signaling, we showed that quantitative control of BACH2 protein level by a small molecule drug fine-tuned the degree of stemness and exhaustion in CAR T cells. Chemically inducing temporal BACH2 activation during manufacture of GD2 CAR T cells imprinted greater antitumor immunity against solid tumor after infusion. Together, we show that BACH2 dosage establishes the hierarchy of stem-like CAR T cells and can be temporally and tunably controlled in CAR T cells to optimize differentiation and antitumor immunity.
2025-10-06 | GSE283635 | GEO
Project description:We reveal that ionized radiation (IR) induces the expression of m6A reader YTHDF2 in DCs with clinical significance, and the depletion of Ythdf2 in DCs augments the anti-tumor effect of RT. We observed that following IR, SPI-1 promotes the transcription of YTHDF2 in DCs. The IR-induced YTHDF2 in DCs directly targets and degrades m6A-binded Mfng, Aph-1b, and Aph-1c, which are essential for notch activation. YTHDF2 blockades in DCs activates notch signaling to promote the expression of MHC-I family gene Gm8909, thus enhancing cross-priming of CD8+ T cells to afford amplified anti-tumor effect of RT. Pharmacological inhibition of YTHDF2 in DC vaccines contributes to RT efficacy in both local tumor control and distant metastasis suppression. Our findings identify IR-induced YTHDF2 as an immunosuppressor in DCs, reveal the mechanism for regulating anti-tumor immunity, and open a new path for the development of m6A-mRNA targeting therapies.
2025-09-26 | GSE309228 | GEO
Project description:Isolated human T cells was stimulated by anti CD3/CD28 Dynabeads and polarized under Th1 (IL2) or Th9 (IL4 plus TGF beta) condition.After 24 hours, cells were transduced with lentivirus. Medium were renewed every 2 days and cells were maintained at a concentration of 1 million per milliliter. On day 16 of culture total RNA was isolated from CAR-T cells using RNeasy Mini kits (Qiagen) following the manufacturer's instruction. Quality of total RNA was evaluated using RNA 6000 Nano LabChip. Qualified RNA was subject to next generation sequencing.
2020-09-18 | GSE156075 | GEO
Project description:Immunotherapies with CAR-T cells achieve remarkable success, especially against B-cell malignancies. However, their activity against non-hematopoietic solid tumors is very limited. One central cause of this failure may be that a pro-oxidative tumor microenvironment can downmodulate the activation and migration of T-cells. In contrast to tumor cells, primary T cells have very low levels of antioxidants. This makes them prone to pro-oxidative effects. Oxidation-induced dysregulation of actin cytoskeletal dynamics hinders T-cell migration which allows only low tumor infiltration rates. In addition, the proliferation and the effector functions of T-cells (tumor cell killing) are disrupted. In order to strengthen human CAR-T cells against a pro-oxidative tumor microenvironment, we have increased increase their antioxidant capacity, e.g. by expressing antioxidants. We aimed to characterize the importance of antioxidant empowerment at functional level and at the molecular level. Among the antioxidant systems, thioredoxin1 (TRX1)-empowerment, allowed CAR T cells to retain their capacities for cytolytic immune synapse formation, cytokine release, proliferation, and cytotoxicity under pro-oxidative conditions. At the molecular level, gene expression analysis revealed that a pro-oxidative micromilieu caused a downmodulation of costimulatory and cytokine signals of T cells. One unique focus of this study was also to investigate global influence of reactive oxygen species on protein oxidation in T cells. Therefore, using TRX1 kinetic trapping and consequently mass spectrometry was employed to get insight into global oxidation levels in T cells. This analysis, namely redoxosome analysis, unveiled 196 oxidized proteins which were annotated to regulate several antitumor T cell functions. Taken together, our results provide evidence that TRX1 empowerment can increase CAR T cell efficacy against solid tumors.
2022-11-23 | PXD031073 | Pride
Project description:Microarray analyses were performed to compare gene expression in cultured mouse Th9, Th2 and Treg cells and resting versus activated Th9 cells. Three replicates were analyzed for each culture condition; Th9 unstim, Th2 unstim, Treg unstim, Th9 stim
2014-03-26 | E-GEOD-44937 | biostudies-arrayexpress
Project description:Poor CAR T persistence limits CAR T cell therapies for B cell malignancies and solid tumors1,2. The expression of memory-associated genes such as TCF7 (protein name TCF1) is linked to response and long-term persistence in patients3–7, thereby implicating memory programs in therapeutic efficacy. Here, we demonstrate that the pioneer transcription factor, FOXO1, is responsible for promoting memory programs and restraining exhaustion in human CAR T cells. Pharmacologic inhibition or gene editing of endogenous FOXO1 in human CAR T cells diminished the expression of memory-associated genes, promoted an exhaustion-like phenotype, and impaired antitumor activity in vitro and in vivo. FOXO1 overexpression induced a gene expression program consistent with T cell memory and increased chromatin accessibility at FOXO1 binding motifs. FOXO1-overexpressing cells retained function, memory potential, and metabolic fitness during settings of chronic stimulation and exhibited enhanced persistence and antitumor activity in vivo. In contrast, TCF1 overexpression failed to enforce canonical memory programs or enhance CAR T cell potency. Importantly, endogenous FOXO1 activity correlated with CAR T and TIL responses in patients, underscoring its clinical relevance in cancer immunotherapy. Our results demonstrate that memory reprogramming through FOXO1 can enhance the persistence and potency of human CAR T cells and highlights the utility of pioneer factors, which bind condensed chromatin and induce local epigenetic remodeling, for optimizing therapeutic T cell states.
2024-02-29 | GSE255414 | GEO